Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

746
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
746
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.9K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.9K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.2K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.3K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

623
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
623
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

2.2K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global burden of drug-resistant tuberculosis in children: A systematic analysis for the Global Burden of Disease Study.

The European respiratory journal·2026
Same author

Outcomes and Treatment-limiting Adverse Events of Patients Receiving BPaL and BPaL-FQ in California.

Open forum infectious diseases·2026
Same author

Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children.

The Cochrane database of systematic reviews·2025
Same author

Xpert MTB/RIF Ultra assay for pulmonary tuberculosis and rifampicin resistance in adults and adolescents.

The Cochrane database of systematic reviews·2025
Same author

Building an agile state-wide research infrastructure to address COVID-19 and emerging threats: insights from an equity-centered public health and academic collaboration in California.

Frontiers in public health·2025
Same author

Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

American journal of respiratory and critical care medicine·2025

Related Experiment Video

Updated: Mar 20, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Getting to Zero: Tuberculosis Elimination in California.

Pennan M Barry1, Alexander W Kay1, Jennifer M Flood1

  • 1Division of Communicable Disease Control, California Department of Public Health, 850 Marina Bay Parkway, Richmond, CA 94804 USA.

Current Epidemiology Reports
|May 25, 2016
PubMed
Summary

California

Keywords:
TB eliminationTuberculosisTuberculosis epidemiology in CaliforniaTuberculosis prevention

More Related Videos

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.6K
Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.2K

Related Experiment Videos

Last Updated: Mar 20, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K
A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.6K
Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.2K

Area of Science:

  • Public health epidemiology
  • Infectious disease control
  • Tuberculosis (TB) research

Background:

  • Historical TB control strategies in California since 1993.
  • Analysis of TB transmission trends, including pediatric cases and foreign-born populations.
  • Slowing decline in annual TB case counts despite overall reduction.

Approach:

  • Review of historical TB epidemiology in California.
  • Examination of current epidemiologic trends and application of new therapeutic tools.
  • Modeling to assess TB elimination timelines and impact of latent TB infection (LTBI) treatment.

Key Points:

  • California has seen a decrease in TB transmission since 1993, with reduced pediatric cases.
  • A significant portion of TB cases in California are among the foreign-born population, progressing from latent infection.
  • At the current rate, TB elimination in California is projected to take over 100 years.

Conclusions:

  • TB elimination in California requires accelerated case decline beyond current trends.
  • Targeting the estimated 2.1 million individuals with latent TB infection is crucial for progress.
  • Novel approaches are being explored by stakeholders to expedite TB case reduction and prevent disease.